Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP boosted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 277.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,884 shares of the company's stock after acquiring an additional 30,796 shares during the quarter. Brevan Howard Capital Management LP's holdings in Revolution Medicines were worth $1,832,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in Revolution Medicines by 187.1% in the 3rd quarter. Barclays PLC now owns 294,664 shares of the company's stock valued at $13,362,000 after purchasing an additional 192,021 shares during the last quarter. Everence Capital Management Inc. acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at $203,000. Avanza Fonder AB purchased a new stake in shares of Revolution Medicines in the 4th quarter valued at $173,000. Sandy Cove Advisors LLC acquired a new position in Revolution Medicines during the 4th quarter worth about $1,837,000. Finally, KBC Group NV boosted its holdings in Revolution Medicines by 54.6% during the 4th quarter. KBC Group NV now owns 4,979 shares of the company's stock valued at $218,000 after acquiring an additional 1,758 shares during the period. Hedge funds and other institutional investors own 94.34% of the company's stock.

Insider Buying and Selling at Revolution Medicines

In related news, COO Margaret A. Horn sold 3,058 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the transaction, the chief operating officer now directly owns 153,533 shares of the company's stock, valued at $5,993,928.32. This represents a 1.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the completion of the sale, the chief financial officer now directly owns 115,006 shares in the company, valued at $4,489,834.24. This represents a 1.59 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

RVMD has been the topic of a number of research reports. Needham & Company LLC reiterated a "buy" rating and set a $59.00 target price on shares of Revolution Medicines in a report on Tuesday, April 8th. Wedbush reissued an "outperform" rating and set a $67.00 target price on shares of Revolution Medicines in a research note on Monday, April 28th. HC Wainwright increased their price target on Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. UBS Group boosted their price objective on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus reduced their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $66.67.

Revolution Medicines Trading Down 5.9 %

RVMD stock opened at $37.44 on Wednesday. The company has a market capitalization of $6.97 billion, a P/E ratio of -10.43 and a beta of 1.11. The business has a 50 day simple moving average of $37.29 and a 200-day simple moving average of $43.57. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). Research analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.